
PubMed:25527429
Annnotations
Glycan-Motif
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 847-857 | https://glytoucan.org/Structures/Glycans/G57321FI | denotes | Tn antigen |
T2 | 990-996 | https://glytoucan.org/Structures/Glycans/G00031MO | denotes | core 1 |
T3 | 997-1010 | https://glytoucan.org/Structures/Glycans/G17108EX | denotes | blood group A |
T4 | 997-1010 | https://glytoucan.org/Structures/Glycans/G58507AZ | denotes | blood group A |
T5 | 1756-1766 | https://glytoucan.org/Structures/Glycans/G57321FI | denotes | Tn antigen |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
GlyCosmos6-Glycan-Motif-Image
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 847-857 | Glycan_Motif | denotes | Tn antigen | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G57321FI |
T2 | 990-996 | Glycan_Motif | denotes | core 1 | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00031MO |
T3 | 997-1010 | Glycan_Motif | denotes | blood group A | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G58507AZ|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G17108EX |
T5 | 1756-1766 | Glycan_Motif | denotes | Tn antigen | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G57321FI |
GlyCosmos6-Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 847-857 | https://glytoucan.org/Structures/Glycans/G57321FI | denotes | Tn antigen |
T2 | 990-996 | https://glytoucan.org/Structures/Glycans/G00031MO | denotes | core 1 |
T3 | 997-1010 | https://glytoucan.org/Structures/Glycans/G17108EX | denotes | blood group A |
T4 | 997-1010 | https://glytoucan.org/Structures/Glycans/G58507AZ | denotes | blood group A |
T5 | 1756-1766 | https://glytoucan.org/Structures/Glycans/G57321FI | denotes | Tn antigen |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
TextSentencer_T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
TextSentencer_T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
TextSentencer_T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
TextSentencer_T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
TextSentencer_T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
TextSentencer_T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
TextSentencer_T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
TextSentencer_T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
TextSentencer_T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
Glycosmos6-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 847-857 | http://www.glycoepitope.jp/epitopes/EP0021 | denotes | Tn antigen |
T2 | 1756-1766 | http://www.glycoepitope.jp/epitopes/EP0021 | denotes | Tn antigen |
Glycosmos6-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 997-1002 | http://purl.obolibrary.org/obo/MAT_0000083 | denotes | blood |
T2 | 997-1002 | http://purl.obolibrary.org/obo/MAT_0000315 | denotes | blood |
Glycan-GlyCosmos
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 671-677 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T2 | 701-707 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T3 | 847-857 | Glycan | denotes | Tn antigen | https://api.glycosmos.org/wurcs2image/latest/png/binary/G57321FI |
T4 | 990-996 | Glycan | denotes | core 1 | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00031MO |
T5 | 1028-1034 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T6 | 1055-1061 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T7 | 1756-1766 | Glycan | denotes | Tn antigen | https://api.glycosmos.org/wurcs2image/latest/png/binary/G57321FI |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 267-273 | HP_0002664 | denotes | Cancer |
T2 | 520-526 | HP_0002664 | denotes | cancer |
T3 | 717-723 | HP_0002664 | denotes | cancer |
T4 | 1660-1666 | HP_0002664 | denotes | cancer |
T5 | 1770-1776 | HP_0002664 | denotes | cancer |
GlycoBiology-GDGDB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
_T1 | 1314-1316 | http://acgg.asia/db/diseases/gdgdb?con_ui=CON00386 | denotes | nm |
_T2 | 1387-1389 | http://acgg.asia/db/diseases/gdgdb?con_ui=CON00386 | denotes | nm |
GlycoBiology-FMA
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
_T18 | 1777-1782 | FMAID:68646 | denotes | cells |
_T1 | 128-149 | FMAID:167256 | denotes | glycosylated proteins |
_T2 | 128-149 | FMAID:62925 | denotes | glycosylated proteins |
_T3 | 141-149 | FMAID:165447 | denotes | proteins |
_T4 | 141-149 | FMAID:67257 | denotes | proteins |
_T5 | 348-360 | FMAID:82737 | denotes | carbohydrate |
_T6 | 348-360 | FMAID:197276 | denotes | carbohydrate |
_T7 | 437-449 | FMAID:82737 | denotes | carbohydrate |
_T8 | 437-449 | FMAID:197276 | denotes | carbohydrate |
_T9 | 580-593 | FMAID:97740 | denotes | immune system |
_T10 | 580-593 | FMAID:9825 | denotes | immune system |
_T11 | 997-1002 | FMAID:256053 | denotes | blood |
_T12 | 1168-1172 | FMAID:217859 | denotes | rate |
_T13 | 1249-1259 | FMAID:70637 | denotes | transition |
_T14 | 1249-1259 | FMAID:171495 | denotes | transition |
_T15 | 1615-1627 | FMAID:197276 | denotes | carbohydrate |
_T16 | 1615-1627 | FMAID:82737 | denotes | carbohydrate |
_T17 | 1777-1782 | FMAID:169002 | denotes | cells |
uniprot-human
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 774-777 | http://www.uniprot.org/uniprot/Q16305 | denotes | PSM |
T2 | 823-826 | http://www.uniprot.org/uniprot/Q16305 | denotes | PSM |
T3 | 862-865 | http://www.uniprot.org/uniprot/Q16305 | denotes | PSM |
T4 | 888-891 | http://www.uniprot.org/uniprot/Q16305 | denotes | PSM |
T5 | 1524-1527 | http://www.uniprot.org/uniprot/Q16305 | denotes | PSM |
T6 | 1589-1592 | http://www.uniprot.org/uniprot/Q16305 | denotes | PSM |
T7 | 774-777 | http://www.uniprot.org/uniprot/Q9NRF2 | denotes | PSM |
T8 | 823-826 | http://www.uniprot.org/uniprot/Q9NRF2 | denotes | PSM |
T9 | 862-865 | http://www.uniprot.org/uniprot/Q9NRF2 | denotes | PSM |
T10 | 888-891 | http://www.uniprot.org/uniprot/Q9NRF2 | denotes | PSM |
T11 | 1524-1527 | http://www.uniprot.org/uniprot/Q9NRF2 | denotes | PSM |
T12 | 1589-1592 | http://www.uniprot.org/uniprot/Q9NRF2 | denotes | PSM |
uniprot-mouse
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 774-777 | http://www.uniprot.org/uniprot/Q91ZM2 | denotes | PSM |
T2 | 823-826 | http://www.uniprot.org/uniprot/Q91ZM2 | denotes | PSM |
T3 | 862-865 | http://www.uniprot.org/uniprot/Q91ZM2 | denotes | PSM |
T4 | 888-891 | http://www.uniprot.org/uniprot/Q91ZM2 | denotes | PSM |
T5 | 1524-1527 | http://www.uniprot.org/uniprot/Q91ZM2 | denotes | PSM |
T6 | 1589-1592 | http://www.uniprot.org/uniprot/Q91ZM2 | denotes | PSM |
GlycoBiology-NCBITAXON
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 83-89 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T2 | 267-273 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | Cancer |
T3 | 520-526 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T4 | 527-537 | http://purl.bioontology.org/ontology/NCBITAXON/127244 | denotes | mechanisms |
T5 | 717-723 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T6 | 1003-1008 | http://purl.bioontology.org/ontology/STY/T096 | denotes | group |
T7 | 1191-1200 | http://purl.bioontology.org/ontology/NCBITAXON/68933 | denotes | thermally |
T8 | 1426-1434 | http://purl.bioontology.org/ontology/STY/T033 | denotes | findings |
T9 | 1660-1666 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T10 | 1707-1714 | http://purl.bioontology.org/ontology/STY/T033 | denotes | finding |
T11 | 1770-1776 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T12 | 1777-1782 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 128-140 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylated |
T2 | 128-149 | http://purl.obolibrary.org/obo/GO_0006486 | denotes | glycosylated proteins |
T3 | 193-202 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
T4 | 204-217 | http://purl.obolibrary.org/obo/GO_0007155 | denotes | cell adhesion |
T5 | 219-231 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
T6 | 233-248 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
GO-MF
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 393-400 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | binding |
T2 | 880-884 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | bind |
T3 | 393-400 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | binding |
T4 | 880-884 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | bind |
T5 | 393-400 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | binding |
T6 | 880-884 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | bind |
T7 | 393-400 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | binding |
T8 | 880-884 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | bind |
GO-CC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 188-192 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T2 | 204-208 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T3 | 1777-1782 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
T4 | 682-685 | http://purl.obolibrary.org/obo/GO_0005790 | denotes | Ser |
T5 | 712-715 | http://purl.obolibrary.org/obo/GO_0005790 | denotes | Ser |
T6 | 990-994 | http://purl.obolibrary.org/obo/GO_0019013 | denotes | core |
UBERON-AE
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 580-593 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
T2 | 997-1002 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
EDAM-topics
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 7-15 | http://edamontology.org/topic_2839 | denotes | molecule |
T2 | 16-21 | http://edamontology.org/topic_3678 | denotes | study |
T3 | 37-49 | http://edamontology.org/topic_0602 | denotes | interactions |
T4 | 83-89 | http://edamontology.org/topic_2640 | denotes | cancer |
T5 | 90-97 | http://edamontology.org/topic_2830 | denotes | antigen |
T6 | 141-149 | http://edamontology.org/topic_0078 | denotes | proteins |
T7 | 155-168 | http://edamontology.org/topic_3300 | denotes | physiological |
T8 | 267-273 | http://edamontology.org/topic_2640 | denotes | Cancer |
T9 | 348-360 | http://edamontology.org/topic_0152 | denotes | carbohydrate |
T10 | 437-449 | http://edamontology.org/topic_0152 | denotes | carbohydrate |
T11 | 520-526 | http://edamontology.org/topic_2640 | denotes | cancer |
T12 | 621-633 | http://edamontology.org/topic_0602 | denotes | interactions |
T13 | 717-723 | http://edamontology.org/topic_2640 | denotes | cancer |
T14 | 724-732 | http://edamontology.org/topic_2830 | denotes | antigens |
T15 | 784-791 | http://edamontology.org/topic_3678 | denotes | studied |
T16 | 811-821 | http://edamontology.org/topic_3382 | denotes | microscopy |
T17 | 850-857 | http://edamontology.org/topic_2830 | denotes | antigen |
T18 | 942-950 | http://edamontology.org/topic_2830 | denotes | antigens |
T19 | 1111-1123 | http://edamontology.org/topic_0602 | denotes | interactions |
T20 | 1505-1517 | http://edamontology.org/topic_0602 | denotes | interactions |
T21 | 1570-1582 | http://edamontology.org/topic_0602 | denotes | interactions |
T22 | 1615-1627 | http://edamontology.org/topic_0152 | denotes | carbohydrate |
T23 | 1636-1648 | http://edamontology.org/topic_0602 | denotes | interactions |
T24 | 1660-1666 | http://edamontology.org/topic_2640 | denotes | cancer |
T25 | 1667-1674 | http://edamontology.org/topic_2830 | denotes | antigen |
T26 | 1759-1766 | http://edamontology.org/topic_2830 | denotes | antigen |
T27 | 1770-1776 | http://edamontology.org/topic_2640 | denotes | cancer |
EDAM-DFO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 141-149 | http://edamontology.org/format_1208 | denotes | proteins |
T2 | 141-149 | http://edamontology.org/data_1467 | denotes | proteins |
T3 | 310-316 | http://edamontology.org/operation_3435 | denotes | normal |
T4 | 561-572 | http://edamontology.org/operation_2423 | denotes | recognition |
T5 | 1160-1167 | http://edamontology.org/operation_1812 | denotes | loading |
T6 | 1357-1365 | http://edamontology.org/operation_2945 | denotes | analysis |
T7 | 1410-1418 | http://edamontology.org/operation_2945 | denotes | analysis |
GlycoBiology-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 997-1002 | http://purl.obolibrary.org/obo/MAT_0000315 | denotes | blood |
T2 | 997-1002 | http://purl.obolibrary.org/obo/MAT_0000083 | denotes | blood |
GlycoBiology-Motifs
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 997-1008 | http://rdf.glycoinfo.org/glycan/G00066MO | denotes | blood group |
Lectin
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
Lectin_T1 | 80-82 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
Lectin_T2 | 667-669 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
Lectin_T3 | 847-849 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
Lectin_T4 | 859-861 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
Lectin_T5 | 931-933 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
Lectin_T6 | 1521-1523 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
Lectin_T7 | 1586-1588 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
Lectin_T8 | 1657-1659 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
Lectin_T9 | 1756-1758 | https://acgg.asia/db/lfdb/LfDB0021 | denotes | Tn |
GlycoBiology-Epitope
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-GlycoEpitope-B_T1 | 847-857 | http://www.glycoepitope.jp/epitopes/EP0021 | denotes | Tn antigen |
PD-GlycoEpitope-B_T2 | 1756-1766 | http://www.glycoepitope.jp/epitopes/EP0021 | denotes | Tn antigen |
GlyTouCan-IUPAC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
GlycanIUPAC_T1 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G69371PB" | denotes | Thr |
GlycanIUPAC_T2 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G04439TG" | denotes | Thr |
GlycanIUPAC_T3 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G01418RR" | denotes | Thr |
GlycanIUPAC_T4 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G98605AX" | denotes | Thr |
GlycanIUPAC_T5 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G24282OK" | denotes | Thr |
GlycanIUPAC_T6 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G55879EK" | denotes | Thr |
GlycanIUPAC_T7 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G12116BQ" | denotes | Thr |
GlycanIUPAC_T8 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G54590PA" | denotes | Thr |
GlycanIUPAC_T9 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G31652HG" | denotes | Thr |
GlycanIUPAC_T10 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G15155WL" | denotes | Thr |
GlycanIUPAC_T11 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G52301ZX" | denotes | Thr |
GlycanIUPAC_T12 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G04075BC" | denotes | Thr |
GlycanIUPAC_T13 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G40829OF" | denotes | Thr |
GlycanIUPAC_T14 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G29274DI" | denotes | Thr |
GlycanIUPAC_T15 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G50601AY" | denotes | Thr |
GlycanIUPAC_T16 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G52865ZM" | denotes | Thr |
GlycanIUPAC_T17 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G73633QJ" | denotes | Thr |
GlycanIUPAC_T18 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G33319MN" | denotes | Thr |
GlycanIUPAC_T19 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G94717IQ" | denotes | Thr |
GlycanIUPAC_T20 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G50452ZL" | denotes | Thr |
GlycanIUPAC_T21 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G90753WM" | denotes | Thr |
GlycanIUPAC_T22 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G27898GL" | denotes | Thr |
GlycanIUPAC_T23 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G03827YH" | denotes | Thr |
GlycanIUPAC_T24 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G64500BA" | denotes | Thr |
GlycanIUPAC_T25 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G89743XV" | denotes | Thr |
GlycanIUPAC_T26 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G62576QG" | denotes | Thr |
GlycanIUPAC_T27 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G70212CQ" | denotes | Thr |
GlycanIUPAC_T28 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G74708KP" | denotes | Thr |
GlycanIUPAC_T29 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G02394PC" | denotes | Thr |
GlycanIUPAC_T30 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G57814GP" | denotes | Thr |
GlycanIUPAC_T31 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G81521LC" | denotes | Thr |
GlycanIUPAC_T32 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G42918SL" | denotes | Thr |
GlycanIUPAC_T33 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G95238FE" | denotes | Thr |
GlycanIUPAC_T34 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G28403TD" | denotes | Thr |
GlycanIUPAC_T35 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G30379UC" | denotes | Thr |
GlycanIUPAC_T36 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G83583TH" | denotes | Thr |
GlycanIUPAC_T37 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G59548EJ" | denotes | Thr |
GlycanIUPAC_T38 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G47410OV" | denotes | Thr |
GlycanIUPAC_T39 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G88663EK" | denotes | Thr |
GlycanIUPAC_T40 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G90684PG" | denotes | Thr |
GlycanIUPAC_T41 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G44881OW" | denotes | Thr |
GlycanIUPAC_T42 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G54691YO" | denotes | Thr |
GlycanIUPAC_T43 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G19289PT" | denotes | Thr |
GlycanIUPAC_T44 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G23779KC" | denotes | Thr |
GlycanIUPAC_T45 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G94729UX" | denotes | Thr |
GlycanIUPAC_T46 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G34038TZ" | denotes | Thr |
GlycanIUPAC_T47 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G90659JR" | denotes | Thr |
GlycanIUPAC_T48 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G74977VW" | denotes | Thr |
GlycanIUPAC_T49 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G42696WA" | denotes | Thr |
GlycanIUPAC_T50 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G82531XS" | denotes | Thr |
GlycanIUPAC_T51 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G47639GO" | denotes | Thr |
GlycanIUPAC_T52 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G69282NX" | denotes | Thr |
GlycanIUPAC_T53 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G49708JS" | denotes | Thr |
GlycanIUPAC_T54 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G63317ON" | denotes | Thr |
GlycanIUPAC_T55 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G60349YI" | denotes | Thr |
GlycanIUPAC_T56 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G81659AQ" | denotes | Thr |
GlycanIUPAC_T57 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G16289GE" | denotes | Thr |
GlycanIUPAC_T58 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G69569AG" | denotes | Thr |
GlycanIUPAC_T59 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G16884LK" | denotes | Thr |
GlycanIUPAC_T60 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G23450NH" | denotes | Thr |
GlycanIUPAC_T61 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G85052FR" | denotes | Thr |
GlycanIUPAC_T62 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G55485RI" | denotes | Thr |
GlycanIUPAC_T63 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G80596GL" | denotes | Thr |
GlycanIUPAC_T64 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G39656RU" | denotes | Thr |
GlycanIUPAC_T65 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G71284FA" | denotes | Thr |
GlycanIUPAC_T66 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G42091PK" | denotes | Thr |
GlycanIUPAC_T67 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G38798SL" | denotes | Thr |
GlycanIUPAC_T68 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G36670NA" | denotes | Thr |
GlycanIUPAC_T69 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G91582QV" | denotes | Thr |
GlycanIUPAC_T70 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G28625IE" | denotes | Thr |
GlycanIUPAC_T71 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G81304ZT" | denotes | Thr |
GlycanIUPAC_T72 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G82883BK" | denotes | Thr |
GlycanIUPAC_T73 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G46290DK" | denotes | Thr |
GlycanIUPAC_T74 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G68202TJ" | denotes | Thr |
GlycanIUPAC_T75 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G39722QK" | denotes | Thr |
GlycanIUPAC_T76 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G76637LW" | denotes | Thr |
GlycanIUPAC_T77 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G51390WF" | denotes | Thr |
GlycanIUPAC_T78 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G35392PX" | denotes | Thr |
GlycanIUPAC_T79 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G27815EZ" | denotes | Thr |
GlycanIUPAC_T80 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G64374OT" | denotes | Thr |
GlycanIUPAC_T81 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G58333PU" | denotes | Thr |
GlycanIUPAC_T82 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G19695IE" | denotes | Thr |
GlycanIUPAC_T83 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G65617GK" | denotes | Thr |
GlycanIUPAC_T84 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G29832KZ" | denotes | Thr |
GlycanIUPAC_T85 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G05333AM" | denotes | Thr |
GlycanIUPAC_T86 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G46130CG" | denotes | Thr |
GlycanIUPAC_T87 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G57766RG" | denotes | Thr |
GlycanIUPAC_T88 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G03334HH" | denotes | Thr |
GlycanIUPAC_T89 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G46094SV" | denotes | Thr |
GlycanIUPAC_T90 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G98365FX" | denotes | Thr |
GlycanIUPAC_T91 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G85392EJ" | denotes | Thr |
GlycanIUPAC_T92 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G59996WL" | denotes | Thr |
GlycanIUPAC_T93 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G49141OD" | denotes | Thr |
GlycanIUPAC_T94 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G88793VU" | denotes | Thr |
GlycanIUPAC_T95 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G88801WQ" | denotes | Thr |
GlycanIUPAC_T96 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G61612EQ" | denotes | Thr |
GlycanIUPAC_T97 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G23181BS" | denotes | Thr |
GlycanIUPAC_T98 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G77428YW" | denotes | Thr |
GlycanIUPAC_T99 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G06824UZ" | denotes | Thr |
GlycanIUPAC_T100 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G15142RK" | denotes | Thr |
GlycanIUPAC_T101 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G18198RM" | denotes | Thr |
GlycanIUPAC_T102 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G70750SS" | denotes | Thr |
GlycanIUPAC_T103 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G04998YJ" | denotes | Thr |
GlycanIUPAC_T104 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G44379HX" | denotes | Thr |
GlycanIUPAC_T105 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G25683ZO" | denotes | Thr |
GlycanIUPAC_T106 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G35036BA" | denotes | Thr |
GlycanIUPAC_T107 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G98129RB" | denotes | Thr |
GlycanIUPAC_T108 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G00134PL" | denotes | Thr |
GlycanIUPAC_T109 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G26488SP" | denotes | Thr |
GlycanIUPAC_T110 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G02441UD" | denotes | Thr |
GlycanIUPAC_T111 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G21668ZD" | denotes | Thr |
GlycanIUPAC_T112 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G67040OT" | denotes | Thr |
GlycanIUPAC_T113 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G56431YZ" | denotes | Thr |
GlycanIUPAC_T114 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G29667IS" | denotes | Thr |
GlycanIUPAC_T115 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G94122LM" | denotes | Thr |
GlycanIUPAC_T116 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G93233YT" | denotes | Thr |
GlycanIUPAC_T117 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G72035WK" | denotes | Thr |
GlycanIUPAC_T118 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G99855SM" | denotes | Thr |
GlycanIUPAC_T119 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G48723MN" | denotes | Thr |
GlycanIUPAC_T120 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G28558MB" | denotes | Thr |
GlycanIUPAC_T121 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G92768RX" | denotes | Thr |
GlycanIUPAC_T122 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G70136KU" | denotes | Thr |
GlycanIUPAC_T123 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G37935YM" | denotes | Thr |
GlycanIUPAC_T124 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G96902PQ" | denotes | Thr |
GlycanIUPAC_T125 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G14015DN" | denotes | Thr |
GlycanIUPAC_T126 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G83153IV" | denotes | Thr |
GlycanIUPAC_T127 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G73174QP" | denotes | Thr |
GlycanIUPAC_T128 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G67188XY" | denotes | Thr |
GlycanIUPAC_T129 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G35093GE" | denotes | Thr |
GlycanIUPAC_T130 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G13364VQ" | denotes | Thr |
GlycanIUPAC_T131 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G72068FB" | denotes | Thr |
GlycanIUPAC_T132 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G93329DU" | denotes | Thr |
GlycanIUPAC_T133 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G54073VB" | denotes | Thr |
GlycanIUPAC_T134 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G41447UI" | denotes | Thr |
GlycanIUPAC_T135 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G85878MY" | denotes | Thr |
GlycanIUPAC_T136 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G92835HR" | denotes | Thr |
GlycanIUPAC_T137 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G34845TQ" | denotes | Thr |
GlycanIUPAC_T138 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G38916XK" | denotes | Thr |
GlycanIUPAC_T139 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G87709OA" | denotes | Thr |
GlycanIUPAC_T140 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G46661GX" | denotes | Thr |
GlycanIUPAC_T141 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G53431DX" | denotes | Thr |
GlycanIUPAC_T142 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G71815PL" | denotes | Thr |
GlycanIUPAC_T143 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G97173UR" | denotes | Thr |
GlycanIUPAC_T144 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G53453JD" | denotes | Thr |
GlycanIUPAC_T145 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G48975CP" | denotes | Thr |
GlycanIUPAC_T146 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G87775XT" | denotes | Thr |
GlycanIUPAC_T147 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G48463GY" | denotes | Thr |
GlycanIUPAC_T148 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G54042BQ" | denotes | Thr |
GlycanIUPAC_T149 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G99993MV" | denotes | Thr |
GlycanIUPAC_T150 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G81407LL" | denotes | Thr |
GlycanIUPAC_T151 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G46430YF" | denotes | Thr |
GlycanIUPAC_T152 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G86548QQ" | denotes | Thr |
GlycanIUPAC_T153 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G25645HZ" | denotes | Thr |
GlycanIUPAC_T154 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G73880WZ" | denotes | Thr |
GlycanIUPAC_T155 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G12979RT" | denotes | Thr |
GlycanIUPAC_T156 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G36146RU" | denotes | Thr |
GlycanIUPAC_T157 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G23944RZ" | denotes | Thr |
GlycanIUPAC_T158 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G67041BN" | denotes | Thr |
GlycanIUPAC_T159 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G95408HX" | denotes | Thr |
GlycanIUPAC_T160 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G31094CC" | denotes | Thr |
GlycanIUPAC_T161 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G99598GU" | denotes | Thr |
GlycanIUPAC_T162 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G94072IC" | denotes | Thr |
GlycanIUPAC_T163 | 1066-1069 | "http://rdf.glycoinfo.org/glycan/G09523ZS" | denotes | Thr |
performance-test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 997-1002 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
PD-UBERON-AE-B_T2 | 580-593 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
mondo_disease
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 83-89 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T2 | 219-231 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T3 | 267-273 | Disease | denotes | Cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T4 | 520-526 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T5 | 717-723 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T6 | 1660-1666 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T7 | 1770-1776 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
Anatomy-MAT
Id | Subject | Object | Predicate | Lexical cue | mat_id |
---|---|---|---|---|---|
T1 | 997-1002 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/MAT_0000083|http://purl.obolibrary.org/obo/MAT_0000315 |
HP-phenotype
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 83-89 | Phenotype | denotes | cancer | HP:0002664 |
T2 | 267-273 | Phenotype | denotes | Cancer | HP:0002664 |
T3 | 520-526 | Phenotype | denotes | cancer | HP:0002664 |
T4 | 717-723 | Phenotype | denotes | cancer | HP:0002664 |
T5 | 1660-1666 | Phenotype | denotes | cancer | HP:0002664 |
T6 | 1770-1776 | Phenotype | denotes | cancer | HP:0002664 |
GlyCosmos15-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 83-89 | Phenotype | denotes | cancer | HP:0002664 |
T2 | 267-273 | Phenotype | denotes | Cancer | HP:0002664 |
T3 | 520-526 | Phenotype | denotes | cancer | HP:0002664 |
T4 | 717-723 | Phenotype | denotes | cancer | HP:0002664 |
T5 | 1660-1666 | Phenotype | denotes | cancer | HP:0002664 |
T6 | 1770-1776 | Phenotype | denotes | cancer | HP:0002664 |
GlyCosmos15-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 83-89 | Disease | denotes | cancer | MONDO:0004992 |
T2 | 267-273 | Disease | denotes | Cancer | MONDO:0004992 |
T3 | 520-526 | Disease | denotes | cancer | MONDO:0004992 |
T4 | 717-723 | Disease | denotes | cancer | MONDO:0004992 |
T5 | 1660-1666 | Disease | denotes | cancer | MONDO:0004992 |
T6 | 1770-1776 | Disease | denotes | cancer | MONDO:0004992 |
GlyCosmos15-CL
Id | Subject | Object | Predicate | Lexical cue | cl_id |
---|---|---|---|---|---|
T1 | 1770-1782 | Cell | denotes | cancer cells | http://purl.obolibrary.org/obo/CL:0001064 |
GlyCosmos15-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 580-593 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
T2 | 997-1002 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
TextSentencer_T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
TextSentencer_T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
TextSentencer_T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
TextSentencer_T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
TextSentencer_T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
TextSentencer_T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
TextSentencer_T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
TextSentencer_T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
TextSentencer_T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
GlyCosmos15-Sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-98 | Sentence | denotes | Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
T2 | 99-266 | Sentence | denotes | Mucins are linear, heavily O-glycosylated proteins with physiological roles that include cell signaling, cell adhesion, inflammation, immune response and tumorgenesis. |
T3 | 267-368 | Sentence | denotes | Cancer-associated mucins often differ from normal mucins by presenting truncated carbohydrate chains. |
T4 | 369-594 | Sentence | denotes | Characterization of the binding properties of mucins with truncated carbohydrate side chains could thus prove relevant for understanding their role in cancer mechanisms such as metastasis and recognition by the immune system. |
T5 | 595-822 | Sentence | denotes | In this work, heterotypic interactions of model mucins that possess the Tn (GalNAcαThr/Ser) and T (Galβ1-3GalNAcαThr/Ser) cancer antigens derived from porcine submaxillary mucin (PSM) were studied using atomic force microscopy. |
T6 | 823-1071 | Sentence | denotes | PSM possessing only the Tn antigen (Tn-PSM) was found to bind to PSM analogs possessing a combination of T, Tn and STn antigens as well as biosynthetic analogs of the core 1 blood group A tetrasaccharide (GalNAcα1-3[Fucα1-2] Galβ1-3GalNAcαSer/Thr). |
T7 | 1072-1186 | Sentence | denotes | The rupture forces for the heterotypic interactions ranged from 18- to 31 pN at a force-loading rate of ∼0.5 nN/s. |
T8 | 1187-1419 | Sentence | denotes | The thermally averaged distance from the bound complex to the transition state (xβ) was estimated to be in the range 0.37-0.87 nm for the first barrier of the Bell Evans analysis and within 0.34-0.64 nm based on a lifetime analysis. |
T9 | 1420-1593 | Sentence | denotes | These findings reveal that the binding strength and energy landscape for heterotypic interactions of Tn-PSM with the above mucins, resemble homotypic interactions of Tn-PSM. |
T10 | 1594-1783 | Sentence | denotes | This suggests common carbohydrate epitope interactions for the Tn cancer antigen with the above mucin analogs, a finding that may be important to the role of the Tn antigen in cancer cells. |
GlyCosmos15-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 847-857 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | Tn antigen | http://www.glycoepitope.jp/epitopes/EP0021 |
T2 | 1756-1766 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | Tn antigen | http://www.glycoepitope.jp/epitopes/EP0021 |
GlyCosmos15-FMA
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 580-593 | Body_part | denotes | immune system | FMA:9825 |
T2 | 997-1002 | Body_part | denotes | blood | FMA:9670 |
GlyCosmos15-MAT
Id | Subject | Object | Predicate | Lexical cue | mat_id |
---|---|---|---|---|---|
T1 | 997-1002 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/MAT_0000315 |
GlyCosmos15-Glycan
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 671-677 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T2 | 701-707 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T3 | 847-857 | Glycan | denotes | Tn antigen | https://api.glycosmos.org/wurcs2image/latest/png/binary/G57321FI |
T4 | 990-996 | Glycan | denotes | core 1 | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00031MO |
T5 | 997-1010 | Glycan | denotes | blood group A | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00066MO |
T6 | 1028-1034 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T7 | 1055-1061 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T8 | 1756-1766 | Glycan | denotes | Tn antigen | https://api.glycosmos.org/wurcs2image/latest/png/binary/G57321FI |
GlyCosmos-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 847-857 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | Tn antigen | http://www.glycoepitope.jp/epitopes/EP0021 |
T2 | 1756-1766 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | Tn antigen | http://www.glycoepitope.jp/epitopes/EP0021 |
Anatomy-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 580-593 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
T2 | 997-1002 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
CL-cell
Id | Subject | Object | Predicate | Lexical cue | cl_id |
---|---|---|---|---|---|
T1 | 1770-1782 | Cell | denotes | cancer cells | http://purl.obolibrary.org/obo/CL:0001064 |